Nerivio Press Releases

December 10, 2024

Theranica Advances Migraine Care in 2024 Supported by New Research, an Expanded Indication, a new Chief Medical Officer, and Broader Insurance Coverage

The Nerivio® REN wearable is redefining pediatric migraine care as the only migraine-specific preventive therapy for children under the age of 12.

November 14, 2024

FDA Expands the Age Indication for Nerivio® as the First-and-Only REN Wearable for Migraine Treatment for Children Aged Eight and Above

Children aged eight and up now have a prescribed non-drug option to treat migraine early and potentially prevent long-term disability and disease progression, addressing a critical unmet need in pediatric migraine care.

October 1, 2024

More States Join the Movement: The Nerivio® REN Wearable Now Covered by Arizona, New Jersey, Ohio, and Virginia Medicaid Programs

Following Colorado and Washington D.C., this expansion brings an additional seven million people into a new era of accessible and affordable non-drug migraine treatment.

July 25, 2024

New Study Evaluates Use of the Nerivio® REN Wearable for Treatment of Migraine in Children Under the Age of 12

Nerivio, currently indicated for use in ages 12 and older, demonstrates study results in younger children with migraine.

July 10, 2024

Colorado Medicaid’s Decision to Cover the Nerivio® REN Wearable Expands Access for Nearly Two Million Americans to Drug-Free, Dual Use Migraine Treatment

Colorado Medicaid is the third federally-funded insurance plan to recognize the REN wearable as safe, effective migraine relief for adolescents and adults ages 12 years and older

May 21, 2024

DC Medicaid Becomes the First Medicaid Plan to Cover the Nerivio® REN Wearable, a Non-Drug Treatment for Migraine

This represents the second federally funded insurance plan, after the Veteran Administration (VA), to cover the innovative therapy

February 20, 2024

Theranica’s REN Wearable Becomes the First Ever Non-Pharmacological Migraine Treatment to Receive Commercial Coverage in the USA

Highmark Inc. Publishes Commercial Coverage Policy for Nerivio®,a Drug-Free, Dual Use Treatment for Adolescents and Adults Living with Migraine

December 19, 2023

2023 Marks a Year of Phenomenal Progress for Theranica in Adolescent Migraine Care

Its Leading REN Wearable Device Brings Hope to Adolescents in the Fight Against a Leading Neurologic Disease

November 28, 2023

New Study Found Preventive Impact in Adolescents Who Frequently Used Nerivio® for Abortive Treatment of Migraine

New Frontiers in Pain Research Study Demonstrates a Reduction in Migraine Days in Teenagers Using the REN Wearable

November 14, 2023

Theranica Enters Into Agreement With Dr. Reddy’s for Commercializing Nerivio® in Europe

Commercial Collaboration Follows News of Nerivio®’s Expanded CE Mark Approval as Novel Non-Drug, Dual-Use Migraine Treatment for Adolescents and Adults

October 25, 2023

New Study Demonstrates Consistent Positive Long-Term Adherence and Efficacy of Nerivio® for Treatment of Migraine

Advances in Therapy Publishes Study Finding 12-Month Consistency in Utilization and Efficacy of Non-Drug, Non-Disruptive Wearable to Mitigate Migraine Burden

September 28, 2023

First Migraine Neuroband Addressing Unmet Needs of Adolescents to Debut at 2023 Child Neurology Society Annual Meeting

Theranica to Unveil Groundbreaking New Real-World Data for Nerivio®, a Novel Drug-Free Device for Acute and Preventive Treatment of Migraine

September 12, 2023

New Study Evaluates How Quickly the Migraine Preventive Impact of Nerivio® Starts

Randomized Placebo-Controlled Study Published in Pain Management Evaluated the Preventive Efficacy of the Non-Drug Wearable As Early As After Two Weeks of Usage

August 9, 2023

Nerivio® CE mark indication expanded to preventive and acute treatment of migraine for adolescents and adults

The company prepares for bringing the wearable prescribed device to Europe next year

June 21, 2023

Clinical Study Evaluated Safety of Using Nerivio® for Treating Migraine in Pregnant Women

Controlled Retrospective Study Compared Use of Drug-Free Solution to Standard Care Treatments for Migraine During Pregnancy

May 16, 2023

Using Nerivio® for Migraine Prevention Results in Significant Clinical and Cost-Saving Benefits for Patients, Insurers, and Employers, According to a New Health Economics Study

Nerivio Can Greatly Reduce Payer Expenses Through Reduction of Migraine Headache Days, Productivity Loss, and Healthcare Utilization Costs

April 12, 2023

Nerivio® Proven Effective in Real-World Setting as Drug-Free Acute Treatment of Migraine for Adolescents

Pediatric Neurology Publishes Study Demonstrating Value of Remote Electrical Neuromodulation (REN) Wearable for Young Adults with Migraine

February 28, 2023

Theranica’s Nerivio® Cleared by FDA for Preventive Treatment of Migraine

Novel Prescription Wearable Proven Effective as a Preventive and Acute Treatment for Adolescents and Adults with Migraine

January 10, 2023

Theranica Enters Into Agreement With Dr. Reddy’s for Commercializing Nerivio® in India

The Theranica and Dr. Reddy’s Laboratories agreement will bring Nerivio to millions of people with migraine in India

December 12, 2022

Pennsylvania-based Highmark Inc. Joins Theranica’s Coverage with Evidence Program for Nerivio® Drug-Free Migraine Treatment Device

Members Will Receive Access to Theranica’s Prescribed Wearable Device

October 24, 2022

Point32Health to Pilot Nerivio® Drug-Free Migraine Treatment Device

Theranica’s Evidence-Based Wearable Device will be Offered to Members Covered Under Harvard Pilgrim Health Care and Tufts Health Plan

October 18, 2022

Theranica Achieves Positive Results in Placebo-Controlled Pivotal Trial of Nerivio® for Preventive Treatment of Migraine

Remote Electrical Neuromodulation (REN) device Nerivio® demonstrates significant superiority over placebo, reduces mean number of migraine days per month when used every other day

September 19, 2022

New Study Suggests REN Comparable to Standard Care Prescribed Medications for Acute Treatment of Chronic Migraines

Analysis of Clinical Trial Data Shows No Difference in Effectiveness Outcomes Between Use of Remote Electrical Neuromodulation (REN) Device Nerivio® and Tested Medications

August 29, 2022

Theranica Secures $45 Million Series C Funding Round

Proceeds to Fund U.S. Commercial Expansion of Migraine Treatment Device, Nerivio®. Financing Led by Philadelphia-Based New Rhein Healthcare, Selected Additional Co-Investors to Join Round at Final Closing

February 16, 2022

Peer-Reviewed Study Shows Positive Impact of Nerivio’s® Guided Imagery, Education and Relaxation (GIER) Feature on Migraine Treatment Response

Jan 19, 2022

Large Real-World Evidence Analysis Provides Comprehensive Evaluation of Nerivio® as an Effective Acute Treatment for Migraine

Largest peer-reviewed real-world study of a migraine device demonstrates that remote electrical neuromodulation (REN) provides a safe and effective drug-free acute treatment option for migraine sufferers

December 15, 2021

Healthcare Industry Leader Scott Serota Joins Theranica Board of Directors

Former President and CEO of the Blue Cross Blue Shield Association, Serota Brings Decades of Experience in US Healthcare Leadership

October 18, 2021

Peer-Reviewed Published Study Provides Further Evidence for the Safety and Efficacy of Nerivio® in Patients with Chronic Migraine

Study shows remote electrical neuromodulation (REN) treatment provides relief for migraine headaches, offering a drug-free acute treatment option for people with chronic migraine

October 4, 2021

MC-Rx Formalizes Pharmacy Benefit Coverage for Theranica’s Nerivio®, Providing Millions of Covered Members Access to the Novel Drug-Free Migraine Therapeutic

Agreement Simplifies and Accelerates Patient Access to Effective, Low Side Effect Drug Free Therapy for Acute Treatment of Migraine

August 15, 2021

Theranica Announces the Establishment of a Unique Level II HCPCS Code by the Centers for Medicare and Medicaid Services (CMS)

Granting of the Code Follows Continued Successful Clinical Trials of Nerivio in Adolescent Patients as well as those with Menstrual Migraine

June 30, 2021

Study Compares Nerivio® to Standard Care Medications for Acute Treatment of Migraine in Adolescents

Peer-Reviewed Study Compares Treatment Results from Migraine Medications to Using Nerivio’s Remote Electrical Neuromodulation

June 21, 2021

Peer-Reviewed Study Suggests Nerivio® Effective for Treatment of Acute Menstrual Migraine Headache

20%-25% of women with migraine have menstrual migraine, which is typically associated with greater disability

March 2, 2021

Nerivio® Drug-free Wearable Surpasses 100,000 Migraine Treatments in the US

Nerivio Usage Grows Significantly Following Indication Expansion to Adolescents

February 16, 2021

Veterans Affairs (VA) Signs Agreement with Theranica to Make Nerivio® Acute Migraine Therapeutic Device Available to Veterans

Drug-Free Smartphone-Controlled Wearable Device Will Address Veteran Community, which has Higher Prevalence Migraine Compared to the General Population

January 25, 2021

FDA Approves Theranica’s Nerivio® for Acute Treatment of Migraine in Adolescents

The Prescribed Wearable Device is Now indicated for Patients 12 Years Old and Above

Read Article

October 26, 2020

Nerivio® Receives Clearance of Expanded Indication to Cover Chronic Migraine Patients

Clinical Evidence Supports Efficacy of Theranica’s Prescribed Digital Therapeutic in Adult Chronic Migraine Patients

September 17, 2020

Largescale Real-World Migraine Study Solidifies Efficacy And Safety of Theranica’s Nerivio® Device

Peer-Reviewed Post-Marketing Surveillance Study Tested Efficacy and Safety of Remote Electrical Neuromodulation (REN) in Acute Treatment of Migraine

September 8, 2020

Nerivio® Smartphone-Controlled Wearable for Acute Treatment of Migraine Granted CE Mark for Use in Europe

Theranica Announces Nerivio will be Available in Select European Countries Starting in 2021

July 16, 2020

KRAIBURG TPE supplies custom-colored medical-grade thermoplastic elastomer for Nerivio, an innovative drug-free neuromodulation therapeutic wearable from Theranica

Nerivio®, a novel wireless neuromodulation wearable from Theranica for drug-free acute treatment of migraine, features an electronic housing molded in a THERMOLAST® M custom-colored medical-grade thermoplastic elastomer compound from KRAIBURG TPE.

July 15, 2020

Theranica Reports Positive Study Results of Nerivio® for Chronic Migraine Patients

New Peer-Reviewed Article Publishes Results of Clinical Study Testing Efficacy of Remote Electrical Neuromodulation in Acute Treatment of Migraine in Chronic Migraine Patients

May 18, 2020

Theranica Expands Executive Team Amid Growing US Demand for Its FDA-authorized Migraine Treatment Wearable Device

During Initial Limited Commercial Launch, Nerivio® Was Used more than 30,000 Times to Address Migraine Pain and other Symptoms

April 6, 2020

Theranica Expands Access to Prescribed Migraine Wearable Nerivio™ Through Partnership With UpScript Health Telemedicine Platform

FDA-Authorized Drug-Free Migraine Treatment Device Available by Prescription through One-Stop Telemedicine Platform

March 10, 2020

Theranica Named to Fast Company’s Annual List of the World’s Most Innovative Companies for 2020

Developer of Nerivio™, a Drug-Free Therapeutic Wearable for the Acute Treatment of Migraine, Recognized as a Leading Biotech Innovator

February 25, 2020

Theranica Expands Accessibility of Nerivio™ to U.S. Migraine Patients Via Partnership With Telemedicine Platform, Cove

Cove Provides Rapid Consultation with a Licensed Physician and Home Delivery of the Novel FDA-Authorized Prescribed Wearable Device

December 18, 2019

Theranica Named 2020 ‘Game Changer’ by CB Insights

BioMed Tech Developer Included in “Electro-Charged Therapeutics” Category Recognizing Companies Creating a Drug-Free Future

December 3, 2019

Theranica: Journal of Expert Review of Medical Devices Publishes Profile of Nerivio

Review Highlights Efficacy and Safety of Smartphone-Controlled Prescribed Wearable for the Acute Treatment of Migraine

November 21, 2019

Theranica’s Nerivio™ Named in TIME’s List of 100 Best Inventions of 2019

Acute Migraine Smartphone-Controlled Prescription Wearable Recognized in Health Care Category

November 18, 2019

Theranica Announces U.S. Recycling Partnership in Commitment to Sustainable Medical Device Production

Partnership Advances Circular Economy by Making Nerivio™, a Prescribed Wearable for Acute Treatment of Migraine, Recyclable

July 23, 2019

New Publication Compares Remote Electrical Neuromodulation for Acute Treatment of Migraine to Treatment with Acute Medications

Headache Researchers in California and Missouri Conducted a Per-Patient Comparison of FDA-Cleared Wearable Device with Contemporary Usual Care

June 24, 2019

Theranica Appoints Senior Executives to Lead its New USA Subsidiary

New Executive Team Will Oversee US Commercialization of FDA-Cleared Nerivio™ for Acute Treatment of Migraine

May 28, 2019

FDA Grants Theranica De Novo to Market First Smartphone-Controlled Acute Migraine-Relief Wearable Device

Clinical Data Show 66.7% Pain Relief Response Within Two Hours

May 13, 2019

OMRON VENTURES Joins Theranica’s Series B Funding Round as Strategic Investor

Strategic investment signals positive response of healthcare community to Theranica’s new approach to migraine management

March 18, 2019

Theranica Raises $35M to Bring Innovative Migraine Device to the USA aMoon leads round B of financing of the Israel-based company

aMoon leads round B of financing of the Israel-based company

November 15, 2018

Theranica Announces Results from Pivotal Study of Device for Treating Acute Migraine

Results of largest study with a migraine device solidify safety, efficacy and tolerability of the drug-free Nerivio Migra, offering huge clinical benefit for migraineurs

July 03, 2017

Theranica Raises $6M to Combat Migraine

Lightspeed leads round A of financing in Israel-based advanced e-health company